Verinata wins US patent for fetal aneuploidy determination method
The new patent covers methods for determining the presence or absence of a fetal aneuploidy, or an abnormal number of fetal chromosomes, by analysis of blood samples from
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.